News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,993 Results
Type
Article (43738)
Company Profile (473)
Press Release (694769)
Multimedia
Podcasts (125)
Webinars (20)
Section
Business (209338)
Career Advice (2041)
Deals (36154)
Drug Delivery (120)
Drug Development (83979)
Employer Resources (174)
FDA (16703)
Job Trends (15194)
News (354214)
Policy (33293)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2661)
Accelerated approval (37)
Adcomms (28)
Allergies (149)
Alliances (51115)
ALS (179)
Alzheimer's disease (1738)
Antibody-drug conjugate (ADC) (335)
Approvals (16946)
Artificial intelligence (554)
Autoimmune disease (167)
Automation (42)
Bankruptcy (373)
Best Places to Work (11843)
BIOSECURE Act (20)
Biosimilars (197)
Biotechnology (331)
Bladder cancer (165)
Brain cancer (61)
Breast cancer (660)
Cancer (5006)
Cardiovascular disease (426)
Career advice (1726)
Career pathing (38)
CAR-T (295)
CDC (48)
Celiac Disease (2)
Cell therapy (790)
Cervical cancer (36)
Clinical research (71521)
Collaboration (1823)
Company closure (4)
Compensation (1202)
Complete response letters (67)
COVID-19 (2775)
CRISPR (102)
C-suite (908)
Cystic fibrosis (152)
Data (6413)
Decentralized trials (2)
Denatured (40)
Depression (146)
Diabetes (509)
Diagnostics (6776)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (273)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (248)
Earnings (91555)
Editorial (62)
Employer branding (21)
Employer resources (153)
Events (121194)
Executive appointments (1017)
FDA (19903)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1552)
Gene editing (218)
Generative AI (46)
Gene therapy (651)
GLP-1 (1014)
Government (4769)
Grass and pollen (6)
Guidances (385)
Healthcare (19219)
HIV (64)
Huntington's disease (47)
IgA nephropathy (88)
Immunology and inflammation (280)
Immuno-oncology (66)
Indications (120)
Infectious disease (3058)
Inflammatory bowel disease (206)
Inflation Reduction Act (17)
Influenza (122)
Intellectual property (259)
Interviews (316)
IPO (16933)
IRA (53)
Job creations (3714)
Job search strategy (1440)
JPM (66)
Kidney cancer (16)
Labor market (86)
Layoffs (582)
Leadership (34)
Legal (8033)
Liver cancer (93)
Longevity (15)
Lung cancer (678)
Lymphoma (388)
Machine learning (43)
Management (59)
Manufacturing (829)
MASH (172)
Medical device (13935)
Medtech (13992)
Mergers & acquisitions (20307)
Metabolic disorders (1332)
Multiple sclerosis (169)
NASH (19)
Neurodegenerative disease (347)
Neuropsychiatric disorders (98)
Neuroscience (3054)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4588)
Now hiring (68)
Obesity (638)
Opinion (287)
Ovarian cancer (169)
Pain (207)
Pancreatic cancer (237)
Parkinson's disease (300)
Partnered (34)
Patents (512)
Patient recruitment (513)
Peanut (58)
People (60380)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22496)
Phase 2 (31532)
Phase 3 (23309)
Pipeline (5537)
Policy (303)
Postmarket research (2602)
Preclinical (9614)
Press Release (67)
Prostate cancer (249)
Psychedelics (56)
Radiopharmaceuticals (303)
Rare diseases (909)
Real estate (6065)
Recruiting (71)
Regulatory (25091)
Reports (53)
Research institute (2492)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (21)
RSV (81)
Schizophrenia (158)
Series A (257)
Series B (203)
Service/supplier (11)
Sickle cell disease (105)
Special edition (27)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3806)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (85)
The Weekly (83)
Vaccines (1044)
Venture capital (96)
Weight loss (412)
Women's health (96)
Worklife (19)
Date
Today (31)
Last 7 days (597)
Last 30 days (2312)
Last 365 days (30652)
2026 (4148)
2025 (31065)
2024 (36297)
2023 (41015)
2022 (52277)
2021 (56763)
2020 (54926)
2019 (47422)
2018 (35699)
2017 (33024)
2016 (32351)
2015 (38401)
2014 (32194)
2013 (27114)
2012 (29222)
2011 (29866)
2010 (27996)
Location
Africa (754)
Alabama (91)
Alaska (7)
Arizona (320)
Arkansas (14)
Asia (40729)
Australia (6770)
California (11634)
Canada (3347)
China (1148)
Colorado (490)
Connecticut (504)
Delaware (344)
Europe (89353)
Florida (1722)
Georgia (365)
Hawaii (3)
Idaho (61)
Illinois (899)
India (71)
Indiana (533)
Iowa (24)
Japan (444)
Kansas (131)
Kentucky (42)
Louisiana (27)
Maine (72)
Maryland (1420)
Massachusetts (8451)
Michigan (330)
Minnesota (644)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (122)
New Hampshire (84)
New Jersey (3093)
New Mexico (31)
New York (3046)
North Carolina (1552)
North Dakota (9)
Northern California (5673)
Ohio (343)
Oklahoma (21)
Oregon (45)
Pennsylvania (2335)
Puerto Rico (24)
Rhode Island (49)
South America (1122)
South Carolina (67)
South Dakota (1)
Southern California (4514)
Tennessee (178)
Texas (1786)
United States (41385)
Utah (346)
Vermont (1)
Virginia (272)
Washington D.C. (82)
Washington State (966)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
738,993 Results for "cara therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
April 15, 2025
·
7 min read
Business
Cara Therapeutics Reports First Quarter 2024 Financial Results
Cara Therapeutics, Inc., a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the first quarter ended March 31, 2024.
May 13, 2024
·
10 min read
Pharm Country
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP).
June 12, 2024
·
3 min read
Press Releases
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics
April 14, 2025
·
5 min read
Pharm Country
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.
April 2, 2024
·
1 min read
Business
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.
March 4, 2024
·
16 min read
Business
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
Cara Therapeutics, Inc., a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close.
May 6, 2024
·
1 min read
Press Releases
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
December 18, 2024
·
16 min read
Business
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update.
February 12, 2024
·
1 min read
Business
Cara Therapeutics Reports Third Quarter 2023 Financial Results
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the third quarter ended September 30, 2023.
November 13, 2023
·
11 min read
1 of 73,900
Next
